Literature DB >> 19637337

Need for standardization in population-based quality of life studies: a review of the current literature.

Marte Lie Hoivik1, Tomm Bernklev, Bjorn Moum.   

Abstract

In this systematic review we focus on the current use of and knowledge on health related quality of life in unselected, population-based IBD cohorts. We made a systematic literature search and included for comprehensive review papers that described a population-based cohort and that used validated HRQoL instruments. We show that even studies defined by the authors as population-based do not always meet the criteria set for being population-based. The heterogeneity of the study populations we have reviewed emphasizes that "population-based" must be defined very meticulously and that study populations need to be scrutinized with regard to all characteristics of the cohort before one can compare their results. Different definitions of study populations as population-based affect outcomes. We also show that use of the same HRQoL questionnaires does not guarantee comparable results as there are several different versions of the questionnaires, the different translations are not always comparable and at last there are several methods of computing and presenting the data. Detailed accumulation of knowledge and thorough meta analyses is therefore difficult hence we find it necessary to raise a discussion on the need of standardization in this field of research and we make some simple recommendations on factors we find important.

Mesh:

Year:  2010        PMID: 19637337     DOI: 10.1002/ibd.21032

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  7 in total

1.  Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort.

Authors:  Lea K Christiansen; Bobby Lo; Flemming Bendtsen; Ida Vind; Marianne K Vester-Andersen; Johan Burisch
Journal:  United European Gastroenterol J       Date:  2019-05-17       Impact factor: 4.623

Review 2.  Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.

Authors:  Fanni Rencz; Márta Péntek; Martin Bortlik; Edyta Zagorowicz; Tibor Hlavaty; Andrzej Śliwczyński; Mihai M Diculescu; Limas Kupcinskas; Krisztina B Gecse; László Gulácsi; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

3.  The Influence of the Inflammatory Bowel Diseases on the Perceived Stress and Quality of Life in a Sample of the South-Western Romanian Population.

Authors:  Denisa-Elena Popa; Mihail-Cristian Pîrlog; Dragoş-Ovidiu Alexandru; Dan-Ionuţ Gheonea
Journal:  Curr Health Sci J       Date:  2022-03-31

4.  Worries and Concerns among Inflammatory Bowel Disease Patients Followed Prospectively over One Year.

Authors:  Lars-Petter Jelsness-Jørgensen; Bjørn Moum; Tomm Bernklev
Journal:  Gastroenterol Res Pract       Date:  2011-09-06       Impact factor: 2.260

5.  Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis.

Authors:  Gert Huppertz-Hauss; Marte Lie Høivik; Ebbe Langholz; Selwyn Odes; Milada Småstuen; Reinhold Stockbrugger; Geir Hoff; Bjørn Moum; Tomm Bernklev
Journal:  Inflamm Bowel Dis       Date:  2015-02       Impact factor: 5.325

6.  Cognitive behavioural therapy for the management of inflammatory bowel disease-fatigue with a nested qualitative element: study protocol for a randomised controlled trial.

Authors:  Micol Artom; Wladyslawa Czuber-Dochan; Jackie Sturt; Christine Norton
Journal:  Trials       Date:  2017-05-11       Impact factor: 2.279

7.  Access to biologicals in Crohn's disease in ten European countries.

Authors:  Márta Péntek; Peter L Lakatos; Talitha Oorsprong; László Gulácsi; Milena Pavlova; Wim Groot; Fanni Rencz; Valentin Brodszky; Petra Baji
Journal:  World J Gastroenterol       Date:  2017-09-14       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.